{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:43:32Z","timestamp":1792514612401,"version":"4.5.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T00:00:00Z","timestamp":1660435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T00:00:00Z","timestamp":1660435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s40257-022-00719-7","type":"journal-article","created":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T10:02:31Z","timestamp":1660471351000},"page":"869-879","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review"],"prefix":"10.1007","volume":"23","author":[{"given":"Chang-Yu","family":"Hsieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1498-1474","authenticated-orcid":false,"given":"Tsen-Fang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,14]]},"reference":[{"key":"719_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.dsi.2018.06.001","volume":"36","author":"H-Y Chiu","year":"2018","unstructured":"Chiu H-Y, Wang T-S, Chen P-H, Hsu S-H, Tsai Y-C, Tsai T-F. Psoriasis in Taiwan: from epidemiology to new treatments. Dermatologica Sin. 2018;36:115\u201323.","journal-title":"Dermatologica Sin"},{"key":"719_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jdermsci.2011.03.002","volume":"63","author":"T-F Tsai","year":"2011","unstructured":"Tsai T-F, Wang T-S, Hung S-T, Tsai PI-C, Schenkel B, Zhang M, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011;63:40\u20136.","journal-title":"J Dermatol Sci"},{"key":"719_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jaad.2015.03.016","volume":"73","author":"C Ohata","year":"2015","unstructured":"Ohata C, Ishii N, Koga H, Fukuda S, Tateishi C, Tsuruta D, et al. Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: a series of 145 cases. J Am Acad Dermatol. 2015;73:50\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2015.03.016.","journal-title":"J Am Acad Dermatol"},{"key":"719_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1046\/j.1365-2133.2000.03367.x","volume":"142","author":"Y Takagi","year":"2000","unstructured":"Takagi Y, Sawada S, Yamauchi M, Amagai M, Niimura M. Coexistence of psoriasis and linear IgA bullous dermatosis. Br J Dermatol. 2000;142:513\u20136.","journal-title":"Br J Dermatol"},{"key":"719_CR5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.2340\/00015555-0832","volume":"90","author":"R Kabashima","year":"2010","unstructured":"Kabashima R, Hino R, Bito T, Kabashima K, Nakamura M, Oyama B, et al. Epidermolysis bullosa acquisita associated with psoriasis. Acta Derm Venereol. 2010;90:314\u20136.","journal-title":"Acta Derm Venereol"},{"key":"719_CR6","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3389\/fimmu.2019.02466","volume":"10","author":"K Kridin","year":"2019","unstructured":"Kridin K, Ahmed AR. Anti-p200 pemphigoid: a systematic review. Front Immunol. 2019;10:2466.","journal-title":"Front Immunol"},{"key":"719_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/ajd.12899","volume":"60","author":"K Phan","year":"2019","unstructured":"Phan K, Goyal S, Murrell DF. Association between bullous pemphigoid and psoriasis: systematic review and meta-analysis of case-control studies. Australas J Dermatol. 2019;60:23\u20138.","journal-title":"Australas J Dermatol"},{"key":"719_CR8","first-page":"283","volume":"70","author":"TT Kobayashi","year":"2002","unstructured":"Kobayashi TT, Elston DM, Libow LF, David-Bajar K. A case of bullous pemphigoid limited to psoriatic plaques. Cutis. 2002;70:283\u20137.","journal-title":"Cutis"},{"key":"719_CR9","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/jdv.17013","volume":"35","author":"S St\u00e4nder","year":"2021","unstructured":"St\u00e4nder S, Schmidt E, Zillikens D, Tha\u00e7i D, Ludwig RJ, Kridin K. Patients with bullous pemphigoid and comorbid psoriasis present with less blisters and lower serum levels of anti-BP180 autoantibodies. J Eur Acad Dermatol Venereol. 2021;35:981\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"719_CR10","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1365-4632.2006.02861.x","volume":"45","author":"A Wilczek","year":"2006","unstructured":"Wilczek A, Sticherling M. Concomitant psoriasis and bullous pemphigoid: coincidence or pathogenic relationship? Int J Dermatol. 2006;45:1353\u20137.","journal-title":"Int J Dermatol"},{"key":"719_CR11","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1111\/jdv.14002","volume":"31","author":"J Loget","year":"2017","unstructured":"Loget J, Pl\u00e9e J, Antonicelli F, Bernard P. A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis. J Eur Acad Dermatol Venereol. 2017;31:e228\u201330.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"719_CR12","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","volume":"82","author":"A Menter","year":"2020","unstructured":"Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82:1445\u201386. https:\/\/doi.org\/10.1016\/j.jaad.2020.02.044.","journal-title":"J Am Acad Dermatol"},{"key":"719_CR13","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.057.","journal-title":"J Am Acad Dermatol"},{"key":"719_CR14","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bjd.13717","volume":"172","author":"C Feliciani","year":"2015","unstructured":"Feliciani C, Joly P, Jonkman MF, Zambruno G, Zillikens D, Ioannides D, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol. 2015;172:867\u201377.","journal-title":"Br J Dermatol"},{"key":"719_CR15","first-page":"2007","volume":"11","author":"PM George","year":"1996","unstructured":"George PM. Bullous pemphigoid possibly induced by psoralen plus ultraviolet A therapy. Photodermatol Photoimmunol Photomed. 1996;11:2007\u20139.","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"719_CR16","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/j.1365-2230.2011.04102.x","volume":"36","author":"J Kluk","year":"2011","unstructured":"Kluk J, Goulding JMR, Bhat J, Finch TM. Drug-induced bullous pemphigoid: cases triggered by intravenous iodine and etanercept. Clin Exp Dermatol. 2011;36:871\u20133.","journal-title":"Clin Exp Dermatol"},{"key":"719_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa011592","volume":"346","author":"S Patients","year":"2002","unstructured":"Patients S, Joly P, Roujeau J-C, Benichou J, Picard C, Dreno B, et al. Comparison of oral and topical coricosterids in patients with bullous emphigoid a comparison of oral and topical corticosteroids in patients. N Engl J Med. 2002;346:321\u20137.","journal-title":"N Engl J Med"},{"key":"719_CR18","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/bjd.12276","volume":"168","author":"EJ Samarasekera","year":"2013","unstructured":"Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. Br J Dermatol. 2013;168:954\u201367.","journal-title":"Br J Dermatol"},{"key":"719_CR19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/jdv.12929","volume":"30","author":"S Tukaj","year":"2016","unstructured":"Tukaj S, Gr\u00fcner D, Tukaj C, Zillikens D, Kasperkiewicz M. Calcitriol exerts anti-inflammatory effects in keratinocytes treated with autoantibodies from a patient with bullous pemphigoid. J Eur Acad Dermatol Venereol. 2016;30:288\u201392.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"719_CR20","first-page":"1","volume":"67","author":"S Tukaj","year":"2020","unstructured":"Tukaj S. Vitamin D in autoimmune bullous disease. Acta Biochim Pol. 2020;67:1\u20135.","journal-title":"Acta Biochim Pol"},{"key":"719_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/1346-8138.13170","volume":"43","author":"N Maki","year":"2016","unstructured":"Maki N, Demitsu T, Umemoto N, Nagashima K, Nakamura T, Kakurai M, et al. Possible paraneoplastic syndrome case of bullous pemphigoid with immunoglobulin G anti-BP180 C-terminal domain antibodies associated with psoriasis and primary macroglobulinemia. J Dermatol. 2016;43:571\u20134.","journal-title":"J Dermatol"},{"key":"719_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1746-1596-9-102","volume":"9","author":"X Si","year":"2014","unstructured":"Si X, Ge L, Xin H, Cao W, Sun X, Li W. Erythrodermic psoriasis with bullous pemphigoid: combination treatment with methotrexate and compound glycyrrhizin. Diagn Pathol. 2014;9:2\u20135.","journal-title":"Diagn Pathol"},{"key":"719_CR23","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/j.1365-4632.2004.02517.x","volume":"45","author":"MA Barnadas","year":"2006","unstructured":"Barnadas MA, Gilaberte M, Pujol R, Agust\u00ed M, Gelp\u00ed C, Alomar A. Bullous pemphigoid in a patient with psoriasis during the course of PUVA therapy: study by ELISA test. Int J Dermatol. 2006;45:1089\u201392.","journal-title":"Int J Dermatol"},{"key":"719_CR24","first-page":"265","volume":"19","author":"E Querol-Cisneros","year":"2021","unstructured":"Querol-Cisneros E, Moreno-Artero E, Rodr\u00edguez-Garijo N, Tom\u00e1s-Vel\u00e1zquez A, Querol I, Ishii N, et al. Bullous pemphigoid without detection of autoantibodies in a patient with psoriasis under ustekinumab. J Ger Soc Dermatol. 2021;19:265\u20137.","journal-title":"J Ger Soc Dermatol"},{"key":"719_CR25","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/1346-8138.12943","volume":"42","author":"C Nakayama","year":"2015","unstructured":"Nakayama C, Fujita Y, Watanabe M, Shimizu H. Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab. J Dermatol. 2015;42:996\u20138.","journal-title":"J Dermatol"},{"key":"719_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jaad.2005.10.055","volume":"54","author":"PS Yamauchi","year":"2006","unstructured":"Yamauchi PS, Lowe NJ, Gindi V. Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol. 2006;54:121\u20132.","journal-title":"J Am Acad Dermatol"},{"key":"719_CR27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S0190-9622(85)70163-6","volume":"13","author":"MH Grunwald","year":"1985","unstructured":"Grunwald MH, David M, Feuerman EJ. Coexistence of psoriasis vulgaris and bullous diseases. J Am Acad Dermatol. 1985;13:224\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"719_CR28","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1684\/ejd.2010.0970","volume":"20","author":"F Cusano","year":"2010","unstructured":"Cusano F, Iannazzone SS, Riccio G, Piccirillo F. Coexisting bullous pemphigoid and psoriasis successfully treated with etanercept. Eur J Dermatol. 2010;20:520.","journal-title":"Eur J Dermatol"},{"key":"719_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000207792","volume":"219","author":"K Monnier-Murina","year":"2009","unstructured":"Monnier-Murina K, Du Thanh A, Merlet-Albran S, Guillot B, Dereure O. Bullous pemphigoid occurring during efalizumab treatment for psoriasis: a paradoxical auto-immune reaction? Dermatology. 2009;219:89\u201390.","journal-title":"Dermatology"},{"key":"719_CR30","first-page":"619","volume":"18","author":"M Lazarczyk","year":"2006","unstructured":"Lazarczyk M, Wozniak K, Ishii N, Gorkiewicz-Petkov A, Hashimoto T, Schwarz R, et al. Coexistence of psoriasis and pemphigoid\u2014only a coincidence? Int J Mol Med. 2006;18:619\u201323.","journal-title":"Int J Mol Med"},{"key":"719_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ejhpharm-2018-001849","volume":"28","author":"M Marin","year":"2021","unstructured":"Marin M, Alzueta N, Castresana M, Gasc\u00f3n A, P\u00edo M. Bullous pemphigoid induced by ustekinumab: a case report. Eur J Hosp Pharm. 2021;28:47\u20139.","journal-title":"Eur J Hosp Pharm"},{"key":"719_CR32","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1111\/1346-8138.14760","volume":"46","author":"M Kamata","year":"2019","unstructured":"Kamata M, Asano Y, Shida R, Maeda N, Yoshizaki A, Miyagaki T, et al. Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid. J Dermatol. 2019;46:e216\u20137.","journal-title":"J Dermatol"},{"key":"719_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/cca.506","author":"J Burch","year":"2014","unstructured":"Burch J, Sebaratnam D. How do prednisolone\/prednisone, alone or in combination with other interventions affect outcomes in people with bullous pemphigoid? Cochrane Clin Ans. 2014. https:\/\/doi.org\/10.1002\/cca.506.","journal-title":"Cochrane Clin Ans"},{"key":"719_CR34","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1001\/archderm.144.5.612","volume":"144","author":"P Kjellman","year":"2008","unstructured":"Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol. 2008;144:612\u20136.","journal-title":"Arch Dermatol"},{"key":"719_CR35","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1590\/abd1806-4841.20198032","volume":"94","author":"P Vargas","year":"2019","unstructured":"Vargas P, Giacaman P, Fern\u00e1ndez J, Morales C. Bullous pemphigoid associated with psoriasis: a good response to methotrexate. An Bras Dermatol. 2019;94:224\u20136.","journal-title":"An Bras Dermatol"},{"key":"719_CR36","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3109\/15569527.2012.667030","volume":"32","author":"U Gunay","year":"2013","unstructured":"Gunay U, Gunduz K, T\u00fcrel Ermertcan A, Kandilo\u01e7lu AR. Coexistence of psoriasis and bullous pemphigoid: remission with low-dose methotrexate. Cutan Ocul Toxicol. 2013;32:168\u20139.","journal-title":"Cutan Ocul Toxicol"},{"key":"719_CR37","first-page":"e19","volume":"98","author":"A Lesniewska","year":"2016","unstructured":"Lesniewska A, Kali\u0144ska-Bienias A, Kowalewski C, Schwartz R, Wozniak K. Development of bullous pemphigoid in a patient with psoriasis and metabolic syndrome. Cutis. 2016;98:e19-23.","journal-title":"Cutis"},{"key":"719_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2478\/sjdv-2018-0018","volume":"10","author":"O Suwarsa","year":"2018","unstructured":"Suwarsa O, Herlina L, Sutedja E, Dharmadji HP, Hindritiani R, Gunawan H. Concurrence of bullous pemphigoid and psoriasis: a case report. Serbian J Dermatol Venereol. 2018;10:124\u20138.","journal-title":"Serbian J Dermatol Venereol."},{"key":"719_CR39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jdcr.2020.12.001","volume":"8","author":"K Svigos","year":"2021","unstructured":"Svigos K, Fried L, Yin L, Brinster N, Lo Sicco K, Adotama P. A new eruption of bullous pemphigoid within psoriatic plaques following cyclosporine withdrawal. JAAD Case Rep. 2021;8:23\u20135. https:\/\/doi.org\/10.1016\/j.jdcr.2020.12.001.","journal-title":"JAAD Case Rep"},{"key":"719_CR40","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2340\/00015555-1619","volume":"94","author":"TS Wang","year":"2014","unstructured":"Wang TS, Tsai TF. Remission of bullous pemphigoid after rituximab treatment in a psoriasis patient on regular low dose methotrexate. Acta Derm Venereol. 2014;94:108\u20139.","journal-title":"Acta Derm Venereol"},{"key":"719_CR41","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4103\/2229-5178.96707","volume":"3","author":"R Rao","year":"2012","unstructured":"Rao R, Yunis F, Chandrashekar B, Gupta A, Handettu S. Coexistence of psoriasis with bullous pemphigoid. Indian Dermatol Online J. 2012;3:119.","journal-title":"Indian Dermatol Online J"},{"key":"719_CR42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1684\/ejd.2016.2888","volume":"27","author":"N Onsun","year":"2017","unstructured":"Onsun N, Sallahoglu K, Dizman D, Su \u00d6, Tosuner Z. Bullous pemphigoid during ustekinumab therapy in a psoriatic patient. Eur J Dermatol. 2017;27:81\u20132.","journal-title":"Eur J Dermatol"},{"key":"719_CR43","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/1346-8138.12798","volume":"42","author":"A Imanishi","year":"2015","unstructured":"Imanishi A, Tateishi C, Imanishi H, Sowa-Osako J, Koga H, Tsuruta D, et al. Pemphigoid with antibodies to laminin \u03b31, BP180 and BP230, associated with psoriasis vulgaris: Successful disease control with cyclosporin. J Dermatol. 2015;42:394\u20137.","journal-title":"J Dermatol"},{"key":"719_CR44","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S0190-9622(08)80058-8","volume":"24","author":"JP Boixeda","year":"1991","unstructured":"Boixeda JP, Soria C, Medina S, Ledo A. Bullous pemphigoid and psoriasis: treatment with cyclosporine. J Am Acad Dermatol. 1991;24:152.","journal-title":"J Am Acad Dermatol"},{"key":"719_CR45","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/ced.12887","volume":"41","author":"P Verma","year":"2016","unstructured":"Verma P, Verma KK, Khanna N, Gupta S, Bhari N. Effectiveness of weekly azathioprine pulse in the treatment of chronic plaque psoriasis: an open-label study. Clin Exp Dermatol. 2016;41:717\u201322.","journal-title":"Clin Exp Dermatol"},{"key":"719_CR46","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1136\/bmj.2.6146.1190","volume":"2","author":"JL Burton","year":"1978","unstructured":"Burton JL, Harman RR, Peachey RD, Warin RP. Azathioprine plus prednisone in treatment of pemphigoid. Br Med J. 1978;2:1190\u20131.","journal-title":"Br Med J"},{"key":"719_CR47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0190-9622(98)70414-1","volume":"39","author":"EJ Primka","year":"1998","unstructured":"Primka EJ, Camisa C. Psoriasis and bullous pemphigoid treated with azathioprine. J Am Acad Dermatol. 1998;39:121\u20133.","journal-title":"J Am Acad Dermatol"},{"key":"719_CR48","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/srep18001","volume":"5","author":"J Pl\u00e9e","year":"2015","unstructured":"Pl\u00e9e J, Le Jan S, Giustiniani J, Barbe C, Joly P, Bedane C, et al. Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome. Sci Rep. 2015;5:18001.","journal-title":"Sci Rep"},{"key":"719_CR49","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/j.1365-2133.2011.10531.x","volume":"165","author":"A Du-Thanh","year":"2011","unstructured":"Du-Thanh A, Merlet S, Maillard H, Bernard P, Joly P, Est\u00e8ve E, et al. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Br J Dermatol. 2011;165:1337\u201343.","journal-title":"Br J Dermatol"},{"key":"719_CR50","first-page":"e539","volume":"53","author":"M Jankowski","year":"2013","unstructured":"Jankowski M, Czajkowski R, Scibior K, Schwartz R. Coexistence of psoriasis vulgaris and vitiligo with bullous pemphigoid: a case report. Int J Dermatol. 2013;53:e539-561.","journal-title":"Int J Dermatol"},{"key":"719_CR51","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/17512433.2019.1665027","volume":"12","author":"YC Tsai","year":"2019","unstructured":"Tsai YC, Tsai TF. A review of antibiotics and psoriasis: induction, exacerbation, and amelioration. Expert Rev Clin Pharmacol. 2019;12:981\u20139. https:\/\/doi.org\/10.1080\/17512433.2019.1665027.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"719_CR52","doi-asserted-by":"crossref","unstructured":"Schwieger-Briel A, Moellmann C, Mattulat B, Schauer F, Kiritsi D, Schmidt E, et al. Bullous pemphigoid in infants: characteristics, diagnosis and treatment. Orphanet J Rare Dis. 2014;9:185. https:\/\/pubmed.ncbi.nlm.nih.gov\/25491396","DOI":"10.1186\/s13023-014-0185-6"},{"key":"719_CR53","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0190-9622(89)80147-1","volume":"20","author":"BM Hisler","year":"1989","unstructured":"Hisler BM, Blumenthal NC, Aronson PJ, Hashimoto K, Rudner EJ. Bullous pemphigoid in psoriatic lesions. J Am Acad Dermatol. 1989;20:683\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"719_CR54","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000431171","volume":"232","author":"JS Sheu","year":"2016","unstructured":"Sheu JS, Divito SJ, Enamandram M, Merola JF. Dapsone therapy for pustular psoriasis: case series and review of the literature. Dermatology. 2016;232:97\u2013101.","journal-title":"Dermatology"},{"key":"719_CR55","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1046\/j.1365-2133.1998.02169.x","volume":"138","author":"F Ameglio","year":"1998","unstructured":"Ameglio F, D\u2019Auria L, Bonifati C, Ferraro C, Mastroianni A, Giacalone B. Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity. Br J Dermatol. 1998;138:611\u20134.","journal-title":"Br J Dermatol"},{"key":"719_CR56","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1111\/j.1365-2230.2008.03204.x","volume":"34","author":"B Stausb\u00f8l-Gr\u00f8n","year":"2009","unstructured":"Stausb\u00f8l-Gr\u00f8n B, Deleuran M, Sommer Hansen E, Kragballe K. Development of bullous pemphigoid during treatment of psoriasis with adalimumab. Clin Exp Dermatol. 2009;34:2008\u20139.","journal-title":"Clin Exp Dermatol"},{"key":"719_CR57","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4103\/idoj.IDOJ_53_19","volume":"11","author":"A Tirado-S\u00e1nchez","year":"2020","unstructured":"Tirado-S\u00e1nchez A, Bonifaz A. Simultaneous bullous pemphigoid and vitiligo associated with adalimumab therapy in a patient with psoriasis vulgaris. Indian Dermatol Online J. 2020;11:229.","journal-title":"Indian Dermatol Online J"},{"key":"719_CR58","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaut.2018.09.003","volume":"96","author":"L Chakievska","year":"2019","unstructured":"Chakievska L, Holtsche MM, K\u00fcnstner A, Goletz S, Petersen BS, Thaci D, et al. IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. J Autoimmun. 2019;96:104\u201312. https:\/\/doi.org\/10.1016\/j.jaut.2018.09.003.","journal-title":"J Autoimmun"},{"key":"719_CR59","first-page":"1","volume":"49","author":"L Lu","year":"2021","unstructured":"Lu L, Yu Y, Zhang J, Fan X, Qi Y, Lin B. Incidental amelioration of bullous pemphigoid during ixekizumab treatment for psoriasis. J Dermatol. 2021;49:1\u20133.","journal-title":"J Dermatol"},{"key":"719_CR60","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1111\/1346-8138.13909","volume":"44","author":"PH Ho","year":"2017","unstructured":"Ho PH, Tsai TF. Development of bullous pemphigoid during secukinumab treatment for psoriasis. J Dermatol. 2017;44:e220\u20131.","journal-title":"J Dermatol"},{"key":"719_CR61","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1365-2230.2007.02603.x","volume":"33","author":"R Saraceno","year":"2008","unstructured":"Saraceno R, Citarella L, Spallone G, Chimenti S. A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy. Clin Exp Dermatol. 2008;33:154\u20135.","journal-title":"Clin Exp Dermatol"},{"key":"719_CR62","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jbspin.2013.02.001","volume":"80","author":"G Ozen","year":"2013","unstructured":"Ozen G, Ergun T, Oner SY, Demirkesen C, Inanc N. Widespread psoriasis induced by rituximab in a patient with rheumatoid arthritis: an unexpected adverse reaction. Jt Bone Spine. 2013;80:545\u20137.","journal-title":"Jt Bone Spine"},{"key":"719_CR63","first-page":"5450863","volume":"2019","author":"HS Alahmari","year":"2019","unstructured":"Alahmari HS, Alhowaish NY, Omair MA. Rituximab-induced psoriasis in a patient with granulomatosis with polyangitis treated with adalimumab. Case Rep Rheumatol. 2019;2019:5450863.","journal-title":"Case Rep Rheumatol"},{"key":"719_CR64","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1111\/pde.12437","volume":"31","author":"L Fiorillo","year":"2014","unstructured":"Fiorillo L, Wang C, Hemmati I. Rituximab induced psoriasis in an infant. Pediatr Dermatol. 2014;31:e149\u201351.","journal-title":"Pediatr Dermatol"},{"key":"719_CR65","first-page":"e289","volume":"27","author":"C Haller","year":"2021","unstructured":"Haller C, Cozzio A, von Kempis J, Rubbert-Roth A. Successful treatment of rituximab-associated palmoplantar pustulosis with apremilast in a patient with seropositive rheumatoid arthritis. J Clin Rheumatol Pract Re Rheum Musculoskelet Dis. 2021;27:e289\u201390.","journal-title":"J Clin Rheumatol Pract Re Rheum Musculoskelet Dis"},{"key":"719_CR66","first-page":"32","volume":"53","author":"S Vural","year":"2019","unstructured":"Vural S, G\u00fcndo\u011fdu M, Ertop P, \u015eanl\u0131 H, Korkmaz P, Heper AO, et al. Ustekinumab associated bullous pemphigoid in a psoriasis patient and a review of the literature. Turkderm Turk Arch Dermatol Venereol. 2019;53:32\u20135.","journal-title":"Turkderm Turk Arch Dermatol Venereol"},{"key":"719_CR67","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaad.2009.02.031","volume":"62","author":"TA Duong","year":"2010","unstructured":"Duong TA, Buffard V, Andr\u00e9 C, Ortonne N, Revuz J, Bagot M, et al. Efalizumab-induced bullous pemphigoid. J Am Acad Dermatol. 2010;62:161\u20132.","journal-title":"J Am Acad Dermatol"},{"key":"719_CR68","first-page":"537","volume":"9","author":"C Roeder","year":"1999","unstructured":"Roeder C, Driesch PV. Psoriatic erythroderma and bullous pemphigoid treated successfully with acitretin and azathioprine. Eur J Dermatol. 1999;9:537\u20139.","journal-title":"Eur J Dermatol"},{"key":"719_CR69","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1365-2133.2007.08333.x","volume":"158","author":"Y Teraki","year":"2008","unstructured":"Teraki Y, Fukuda T. Pemphigoid nodularis associated with psoriatic erythroderma: successful treatment with suplatast tosilate. Br J Dermatol. 2008;158:424\u20136.","journal-title":"Br J Dermatol"},{"key":"719_CR70","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.3760\/cma.j.issn.0366-6999.20140825","volume":"127","author":"ZL Li","year":"2014","unstructured":"Li ZL, Jin PY, Feng SY, Wang BX. Treatment of coexisting bullous pemphigoid and psoriasis with triptergium wilfordii. Chin Med J. 2014;127:3037.","journal-title":"Chin Med J"},{"key":"719_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2022.115090","volume":"289","author":"M Dai","year":"2022","unstructured":"Dai M, Peng W, Zhang T, Zhao Q, Ma X, Cheng Y, et al. Metabolomics reveals the role of PPAR\u03b1 in Tripterygium Wilfordii-induced liver injury. J Ethnopharmacol. 2022;289: 115090.","journal-title":"J Ethnopharmacol"},{"key":"719_CR72","first-page":"833","volume":"9","author":"M Augustin","year":"2011","unstructured":"Augustin M, Sch\u00e4fer I, Reich K, Glaeske G, Radtke M. Systemic treatment with corticosteroids in psoriasis-health care provision far beyond the S3-guidelines. J Ger Soc Dermatol. 2011;9:833\u20138.","journal-title":"J Ger Soc Dermatol"},{"key":"719_CR73","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1111\/j.1468-3083.2012.04656.x","volume":"27","author":"U Mrowietz","year":"2013","unstructured":"Mrowietz U, Domm S. Systemic steroids in the treatment of psoriasis: what is fact, what is fiction? J Eur Acad Dermatol Venereol. 2013;27:1022\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"719_CR74","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0190-9622(88)70216-9","volume":"19","author":"N Tsankov","year":"1988","unstructured":"Tsankov N, Botev-Zlatkov N, Lazarova AZ, Kostova M, Popova L, Tonev S. Psoriasis and drugs: influence of tetracyclines on the course of psoriasis. J Am Acad Dermatol. 1988;19:629\u201332.","journal-title":"J Am Acad Dermatol"},{"key":"719_CR75","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13958","volume":"33","author":"FS Delli","year":"2020","unstructured":"Delli FS, Sotiriou E, Lazaridou E, Apalla Z, Lallas A, Vakirlis E, et al. Total IgE, eosinophils, and interleukins 16, 17A, and 23 correlations in severe bullous pemphigoid and treatment implications. Dermatol Ther. 2020;33: e13958.","journal-title":"Dermatol Ther"},{"key":"719_CR76","doi-asserted-by":"publisher","first-page":"e366","DOI":"10.1111\/ajd.13263","volume":"61","author":"KL Kerkemeyer","year":"2020","unstructured":"Kerkemeyer KL, Pinczewski J, Sinclair R. Successful treatment of recalcitrant lichen planus pemphigoides with tildrakizumab. Australas J Dermatol. 2020;61:e366\u20138.","journal-title":"Australas J Dermatol"},{"key":"719_CR77","first-page":"0","volume":"35","author":"M Burlando","year":"2021","unstructured":"Burlando M, Capurro N, Herzum A, Cozzani E, Parodi A. Guselkumab-associated bullous pemphigoid in a psoriasis patient: a case report and review of the literature. Dermatol Ther. 2021;35:0\u20133.","journal-title":"Dermatol Ther"},{"key":"719_CR78","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","volume":"83","author":"R Abdat","year":"2020","unstructured":"Abdat R, Waldman RA, de Bedout V, Czernik A, Mcleod M, King B, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol. 2020;83:46\u201352.","journal-title":"J Am Acad Dermatol"},{"key":"719_CR79","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jaad.2021.05.013","volume":"86","author":"CM Brumfiel","year":"2022","unstructured":"Brumfiel CM, Patel MH, Zirwas MJ. Development of psoriasis during treatment with dupilumab: a systematic review. J Am Acad Dermatol. 2022;86:708\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"719_CR80","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1001\/jamaophthalmol.2018.3789","volume":"136","author":"S Sarny","year":"2018","unstructured":"Sarny S, Hucke M, El-Shabrawi Y. Treatment of mucous membrane pemphigoid with Janus kinase inhibitor baricitinib. JAMA Ophthalmol. 2018;136:1420\u20132.","journal-title":"JAMA Ophthalmol."},{"key":"719_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101104","volume":"22","author":"H James","year":"2021","unstructured":"James H, Paley GL, Brasington R, Custer PL, Margolis TP, Paley MA. Tofacitinib for refractory ocular mucous membrane pemphigoid. Am J Ophthalmol Case Rep. 2021;22: 101104.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"719_CR82","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1365-2133.1976.tb00873.x","volume":"95","author":"K Thomsen","year":"1976","unstructured":"Thomsen K, Schmidt H. PUVA-induced bullous pemphigoid. Br J Dermatol. 1976;95:568\u20139.","journal-title":"Br J Dermatol"},{"key":"719_CR83","first-page":"105","volume":"19","author":"E Inamura","year":"2021","unstructured":"Inamura E, Tsujiwaki M, Ujiie H, Nishie W, Hata H, Shimizu H, et al. Bullous pemphigoid associated with psoriasis showing marked neutrophilic infiltrates. J Ger Soc Dermatol. 2021;19:105\u20138.","journal-title":"J Ger Soc Dermatol"},{"key":"719_CR84","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1046\/j.1468-3083.2002.00570_12.x","volume":"53","author":"A Pasi\u0107","year":"2002","unstructured":"Pasi\u0107 A, Ljubojevi\u0107 S, Lipozenci\u0107 J, Marinovi\u0107 B, Loncari\u0107 D. Coexistence of psoriasis vulgaris, bullous pemphigoid and vitiligo: a case report. J Eur Acad Dermatol Venereol. 2002;53:426\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"719_CR85","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2133.1985.tb02079.x","volume":"113","author":"CEH Grattan","year":"1985","unstructured":"Grattan CEH. Evidence of an association between bullous pemphigoid and psoriasis. Br J Dermatol. 1985;113:281\u20133.","journal-title":"Br J Dermatol"},{"key":"719_CR86","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2133.2008.08961.x","volume":"160","author":"D Inokuma","year":"2009","unstructured":"Inokuma D, Kodama K, Natsuga K, Kasai M, Abe M, Nishie W, et al. Autoantibodies against type XVII collagen C-terminal domain in a patient with bullous pemphigoid associated with psoriasis vulgaris. Br J Dermatol. 2009;160:451\u20134.","journal-title":"Br J Dermatol"},{"key":"719_CR87","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1365-2230.1991.tb00408.x","volume":"16","author":"WDF Smith","year":"1991","unstructured":"Smith WDF, Lewis Jones MS, Stewart TW, Fernando MU. Bullous pemphigoid occurring in psoriatic plaques in association with Hashimoto\u2019s thyroiditis. Clin Exp Dermatol. 1991;16:389\u201391.","journal-title":"Clin Exp Dermatol"},{"key":"719_CR88","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1684\/ejd.2017.2980","volume":"27","author":"M Ohashi","year":"2017","unstructured":"Ohashi M, Takagi H, Mizutani Y, Seishima M, Koga H, Hashimoto T. Bullous pemphigoid with IgG autoantibodies to the \u03b13 subunit of laminin 332 associated with psoriasis vulgaris. Eur J Dermatol. 2017;27:306\u20137.","journal-title":"Eur J Dermatol"},{"key":"719_CR89","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1001\/archderm.1978.01640230017005","volume":"114","author":"WA Koerber Jr","year":"1978","unstructured":"Koerber WA Jr, Price NM, Watson W. Coexistent psoriasis and bullous pemphigoid: a report of six cases. Arch Dermatol. 1978;114:1643\u20136. https:\/\/doi.org\/10.1001\/archderm.1978.01640230017005.","journal-title":"Arch Dermatol"},{"key":"719_CR90","doi-asserted-by":"publisher","first-page":"208","DOI":"10.4103\/ijd.IJD_794_19","volume":"66","author":"K Yamada","year":"2021","unstructured":"Yamada K, Noto M, Yamakawa T, Manabe M, Osada S-I. Superimposed effects of adalimumab and linagliptin on the development of bullous pemphigoid in a psoriatic patient: a case report. Indian J Dermatol. 2021;66:208\u201310.","journal-title":"Indian J Dermatol"},{"key":"719_CR91","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000246255","volume":"193","author":"S Perl","year":"1996","unstructured":"Perl S, Rappersberger K, F\u00f6dinger D, Anegg B, H\u00f6nigsmann H, Ortel B. Bullous pemphigoid induced by PUVA therapy. Dermatology. 1996;193:245\u20137.","journal-title":"Dermatology"},{"key":"719_CR92","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/j.1365-2133.1996.tb03883.x","volume":"135","author":"G Kirtschig","year":"1996","unstructured":"Kirtschig G, Chow ETY, Venning VA, Wojnarowska FT. Acquired subepidermal bullous diseases associated with psoriasis: a clinical, immunopathological and immunogenetic study. Br J Dermatol. 1996;135:738\u201345.","journal-title":"Br J Dermatol"},{"key":"719_CR93","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1365-2133.1976.tb00865.x","volume":"95","author":"JR Person","year":"1976","unstructured":"Person JR, Rogers RS. Bullous pemphigoid and psoriasis: does subclinical bullous pemphigoid exist? Br J Dermatol. 1976;95:535\u201340.","journal-title":"Br J Dermatol"},{"key":"719_CR94","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1751-7125.2008.07318.x","volume":"7","author":"E Rallis","year":"2008","unstructured":"Rallis E, Anyfantakis V. Coexistent psoriasis and bullous pemphigoid responding to mycophenolate mofetil monotherapy. Skinmed. 2008;7:101\u20132.","journal-title":"Skinmed."},{"key":"719_CR95","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1001\/archderm.1977.01640060141023","volume":"113","author":"AR Ahmed","year":"1977","unstructured":"Ahmed AR, Winkler NW. Psoriasis and bullous pemphigoid. Arch Dermatol. 1977;113:845. https:\/\/doi.org\/10.1001\/archderm.1977.01640060141023.","journal-title":"Arch Dermatol"},{"key":"719_CR96","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/00015550510035677","volume":"85","author":"H Washio","year":"2005","unstructured":"Washio H, Hara H, Suzuki H, Yoshida M, Hashimoto T. Bullous pemphigoid on psoriasis lesions after UVA radiation. Acta Derm Venereol. 2005;85:561\u20133.","journal-title":"Acta Derm Venereol"},{"key":"719_CR97","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jdcr.2015.07.014","volume":"1","author":"A Le Guern","year":"2015","unstructured":"Le Guern A, Alkeraye S, Vermersch-Langlin A, Coupe P, Vonarx M. Bullous pemphigoid during ustekinumab therapy. JAAD Case Rep. 2015;1:359\u201360. https:\/\/doi.org\/10.1016\/j.jdcr.2015.07.014.","journal-title":"JAAD Case Rep"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00719-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00719-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00719-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T18:11:28Z","timestamp":1727806288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00719-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,14]]},"references-count":97,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["719"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00719-7","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,14]]},"assertion":[{"value":"25 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding or sponsorship was received for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Chang-Yu Hsieh has no conflict of interest to disclose. Tsen-Fang Tsai has conducted clinical trials or received honoraria for serving as a consultant for AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli-Lilly, Galderma, Janssen-Cilag, Merck Sharp & Dohme, Novartis International AG, Pfizer Inc., and UCB Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies. Searching strategies are specified in the Methods section.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and consent to publish"}},{"value":"Dr Chang-Yu Hsieh conducted the literature search, summarized the identified papers and drafted the manuscript. Dr Tsen-Fang Tsai is responsible for the ideation of this topic and final refinement of this article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s contribution"}}]}}